96 Tests PN: B411155

Components:

45x Ab-conjugated beads (S4P8 - NHP IL-1RA Ab-bead). PN: B411155A. One vial containing 100 µL of anti-NHP IL-1RA conjugated to AimPlex Bead S4P8.

25x Biotin-detection Ab (NHP IL-1RA Biotin-dAb). PN: B411155B. One vial containing 100 µL of biotinylated anti-NHP IL-1RA.

Lyophilized Standard Mix-NHP Group 1 Panel B. PPN: HG10011. One vial containing lyophilized recombinant Eotaxin, IL-1β, IL-1RA, IL-8, IL-12p70, IL-22, IP-10, MCP-1, MCP-3, and RANTES. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying NHP IL-1RA.  Can be multiplexed with other analytes in Human Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in NHP Group 1: Negligible

  • Sample volume: 15 µL/test

Description:

Interleukin-1 Receptor Antagonist is a member of Interleukin-1 cytokine family. IL1RA binds non-productively to the IL-1 receptor surface, the same receptor that binds to IL-1. IL1RA is secreted by many types of T cells and epithelial cells and adipocytes. It inhibits the pro-inflammatory activities of IL-1 alpha and IL-1 beta, though in vitro, IL1RA appears to have no effect on human T cell responses. It may indicate that IL-1 may not be necessary for T cell proliferation in vitro. IL-1 instigates the production of matrix metalloproteinases and other enzymes damage cartilage. As IL1RA restricts IL-1, a recombinant version of IL1RA is used in the treatment of rheumatoid arthritis. Studies have also  observed a relationship between high levels of IL1RA and schizophrenia.

References:

  1. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest. 1991; 88(5): 1445-1451. Doi: 10.1172./JCI115453.

  2. Jacques C, Gosset M, Berenbaum F, Gabay C. The Role of IL-1 and IL-1RA in Joint Inflammation and Cartilage Degradation. Vitamins & Hormones. 2006; 74: 371-403. Doi: 10.1016/50083-6729(06)74016-X.

  3. Kim SJ, Lee HJ, et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr Genet. 2004; 14(3): 165-7. PMID: 15318032.

  4. Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett. 2006; 580 (27) 6289-94. Doi: 10.1016/j.febslet.2006.10.061.